摘要
目的探讨紫杉醇联合索拉非尼治疗原发性肝癌的临床疗效以及对预后的影响。方法将125例原发性肝癌患者按照治疗方法的不同分为A组(n=62,替吉奥联合索拉非尼)和B组(n=63,紫杉醇联合索拉非尼),比较两组患者临床疗效、不良反应、无进展生存期(PFS)、总生存期(OS)及生活质量。结果B组患者总有效率高于A组患者,差异有统计学意义(P﹤0.05)。治疗期间,B组患者中性粒细胞减少、血小板减少、肝功能损伤、乏力、手足皮肤反应发生率均低于A组患者,差异均有统计学意义(P﹤0.05)。B组患者PFS、OS均明显长于A组,差异均有统计学意义(P﹤0.01)。治疗后,两组患者健康调查简表(SF-36)评分均高于治疗前,且B组患者SF-36评分高于A组,差异均有统计学意义(P﹤0.05)。结论紫杉醇联合索拉非尼治疗原发性肝癌患者可提高总有效率,减少不良反应,在改善预后及提高生活质量中具有一定的临床价值。
Objective To explore the clinical efficacy of paclitaxel combined with sorafenib in primary liver cancer and the effect on prognosis.Method A total of 125 patients with primary liver cancer were divided into group A(n=62,S-1+sorafenib)and group B(n=63,paclitaxel+sorafenib).The clinical efficacy,adverse reactions,progression-free survival(PFS),overall survival(OS),and quality of life were compared between the two groups.Result The total effective rate in group B was higher than that in group A(P<0.05).The incidences of neutropenia,thrombocytopenia,liver function damage,fatigue and cutaneous reaction of hand and foot in group B were lower than those in group A(P<0.05).The PFS and OS in group B were longer than those in group A(P<0.01).After treatment,the scores of the MOS 36-item short form health survey(SF-36)in both groups increased significantly,and the score in group B was significantly higher than that in group A(P<0.05).Conclusion The combined treatment of paclitaxel and sorafenib in patients with primary liver cancer can improve the total effective rate and reduce the adverse reactions,and has certain clinical value in improving the prognosis and quality of life.
作者
孙媛
罗建梅
米晶晶
SUN Yuan;LUO Jianmei;MI Jingjing(Department of Pharmacy,Yulin No.2 Hospital,Yulin 719000,Shaanxi,China;Department of Medicine,Yulin No.2 Hospital,Yulin 719000,Shaanxi,China)
出处
《癌症进展》
2022年第15期1601-1603,共3页
Oncology Progress
